Zealand Pharma A Receivables Turnover Ratio (ZEAL), from the fourth quarter 2021 to the fourth quarter 2020 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Zealand Pharma A  (NASDAQ: ZEAL)
 

Zealand Pharma A Accounts Receivables Turnover Ratio from the fourth quarter 2021 to the fourth quarter 2020

Quarterly Results, Trends, Rankings, Statistics


Zealand Pharma A's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2021 to a ratio of 0.81, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the fourth quarter 2021. Average receivable collection period, for the Zealand Pharma A in Dec 31 2021 quarter, has decreased to 451 days, compared to 2281 days, in the 0 quarter.

If we take a look into Healthcare sector 492 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2021 from 0 to 3478.

What is Receivable Turnover Ratio?
What is Zealand Pharma A Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZEAL Receivables Turnover Ratio (Dec 31 2021)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Sep 30 2020)
III. Quarter
Y / Y Receivable Change 45.46 % 948.31 % 64615.12 % 14436.08 % 733.24 %
Y / Y Revenue Change 424.05 % - - - -
Receivable Turnover Ratio (TTM) 0.81 0.16 0.26 0.47 2.72
ZEAL's Total Ranking # 3478 # 0 # 0 # 0 #
Accounts Receivable average collection period days 451 2329 1415 773 134
Seq. Receivable Change -84.78 % 0 % 0 % 855.76 % 9.68 %
Seq. Revenue Change - - - - 500.78 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 176
Healthcare Sector # 493
Overall Market # 3478

Receivable Turnover Ratio Statistics
High Average Low
0.14 0.14 0.14
(Dec 31 2021)  





ZEAL Company Profile • Back to ZEAL Efficiency Comparisons • Compare ZEAL Receivables Turnover Ratio to its Competitors

Financial Statements
Zealand Pharma A's Accounts Receivable $ 11 Millions Visit ZEAL's Balance sheet
Zealand Pharma A's Sales TTM $ 47 Millions Visit ZEAL's Income Statement
Sources of ZEAL's Revenues Visit ZEAL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ZEAL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ZEAL's Growth Rates ZEAL's Roa ZEAL's Inventory Turnover Ratio ZEAL's Dividend Comparisons
ZEAL's Profitability Ratios ZEAL's Roi ZEAL's Asset Turnover Ratio ZEAL's Dividend Growth
ZEAL's Valuation Ratios ZEAL's Roe ZEAL's Financial Strength Ratios ZEAL's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2021, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Dec 31 2021 Receivable at quarter ending Dec 31 2021
International Stem Cell Corporation  11.50 $ 7.176  Millions$ 0.624  Millions
Regenxbio Inc   11.48 $ 470.347  Millions$ 40.972  Millions
Icu Medical Inc  11.37 $ 1,316.308  Millions$ 115.771  Millions
Conformis inc   11.36 $ 99.860  Millions$ 8.787  Millions
Zimvie Inc   11.34 $ 1,014.649  Millions$ 89.475  Millions
Integrated Biopharma Inc  11.28 $ 61.475  Millions$ 5.452  Millions
Lensar Inc   11.27 $ 34.459  Millions$ 3.059  Millions
Mymetics Corporation  11.26 $ 0.509  Millions$ 0.045  Millions
Procept Biorobotics Corporation  11.15 $ 34.474  Millions$ 3.092  Millions
Erytech Pharma S a   11.15 $ 0.151  Millions$ 0.014  Millions
Milestone Scientific Inc   11.13 $ 10.305  Millions$ 0.926  Millions
National Healthcare Corp  11.10 $ 1,074.302  Millions$ 96.812  Millions
Arvinas Inc   11.07 $ 46.700  Millions$ 4.220  Millions
Solana Company  11.05 $ 0.522  Millions$ 0.047  Millions
Abiomed Inc   11.01 $ 1,003.148  Millions$ 91.086  Millions
Karyopharm Therapeutics Inc   10.90 $ 209.819  Millions$ 19.245  Millions
Butterfly Network Inc   10.87 $ 62.565  Millions$ 5.756  Millions
Inogen Inc   10.79 $ 358.003  Millions$ 33.182  Millions
Pulmatrix Inc   10.72 $ 5.169  Millions$ 0.482  Millions
Talphera Inc   10.49 $ 2.818  Millions$ 0.269  Millions
Biolase Inc   10.48 $ 39.188  Millions$ 3.740  Millions
Utah Medical Products Inc  10.47 $ 49.054  Millions$ 4.687  Millions
Imac Holdings Inc   10.37 $ 14.386  Millions$ 1.388  Millions
Grifols Sa  10.32 $ 5,836.065  Millions$ 565.570  Millions
Rockwell Medical inc   10.30 $ 61.580  Millions$ 5.976  Millions
Somalogic Inc   10.28 $ 81.626  Millions$ 7.941  Millions
Sunlink Health Systems Inc   10.17 $ 44.697  Millions$ 4.394  Millions
Option Care Health Inc   10.14 $ 3,438.640  Millions$ 338.997  Millions
Nrc Health  10.13 $ 147.954  Millions$ 14.611  Millions
Allied Healthcare Products inc   10.07 $ 29.150  Millions$ 2.894  Millions

Date modified: 2026-09-09T12:37:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.